Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study by unknown
ORAL PRESENTATION Open Access
Synthetic HIV-1 matrix protein p17-based AT20-KLH
therapeutic immunization in HIV-1-infected
patients receiving antiretroviral treatment: A phase
I safety and immunogenicity study
Arnaldo Caruso*, Marialuisa Iaria, Francesca Caccuri, Cinzia Giagulli, Simona Fiorentini
From International Symposium HIV and Emerging Infectious Diseases 2014
Marseille, France. 21-23 May 2014
Introduction
Therapeutic vaccination is a promising approach to treat
HIV-1+ people by boosting or redirecting immune sys-
tem to neutralize HIV-1 antigens whose effects are rele-
vant to viral pathogenesis. HIV-1 matrix protein p17 is a
structural protein that, through the interaction of its
NH2-residing epitope AT20 with specific receptor(s),
acts extracellularly as a viral toxin. In fact, p17 is able to
deregulate biological activities of different cells involved
in AIDS pathogenesis.
To induce neutralizing antibodies (Abs) to p17 we
developed a peptide-based immunogen (AT20-KLH)
and evaluated its safety and immunogenicity.
Methods
24 asymptomatic HAART-treated HIV-1+ patients were
enrolled in a phase I clinical study and were randomized to
3 groups: 2 groups treated with five IM injection (Arm A:
25 μg/inoculation; Arm B: 100 μg/inoculation) at day 0, 28,
56, 84 and 112; the control group (Arm C), not injected.
Safety was assessed by monitoring local and systemic
adverse events (AEs), recorded till day 168. Evaluation of
immunogenicity was by titering Abs using ELISA.
Results
In all, 105 AEs were reported across the groups. Most
were mild and resolved without sequelae. No significant
changes in the routine laboratory parameters, CD4 T-cell
count or HIV-1 viremia were found. Despite the absence
of anti-AT20 preimmunization Abs, 100% of treated sub-
jects developed high titers of anti-AT20 Abs (GM 9775)
in response to both AT20-KLH doses. These Abs were
also capable of recognizing AT20 within the p17 frame-
work and to neutralize its binding to cell receptors.
Furthermore, we were able to recruit several participants
two years after the first injection to evaluate longevity of
anti-AT20 elicited Abs. 100% of these subjects still
showed anti-AT20 Abs with titers that were about half
the ones detected at the end of immunization protocol.
Conclusion
The AT20 peptide-based approach has allowed to redirect
HAART-treated patients’ humoral responses toward a pre-
viously untargeted hotspot of functional activity. Overall,
the tested AT20-KLH doses were safe and well tolerated,
supporting further exploration of AT20-KLH as an HIV-1
therapeutic vaccine candidate.
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